1. Home
  2. Live Updates
  3. Botensilimab/Balstilimab Breakthrough Data Presented at ASCO

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population

22.01.2024 - Agenus Inc. (Nasdaq: AGEN), a leader in developing immunological cancer treatments, today announced results from the NEST-1 study, an investigator-sponsored trial (IST) evaluating the combination of botensilimab and balstilimab (BOT/BAL) in the ... Seite 1

Related Keywords

, Colon Cancer Research At Weill Cornell Medicine , Nasdaq , Agenus Inc , Microsatellite Stable , Microsatellite Instability High , Pashtoon Kasi , Colon Cancer Research , Weill Cornell Medicine , Cancer Research ,

© 2025 Vimarsana